Please assess the completion status of the following clinical trial:

Trial Title: Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to provide informed consent and comply with study assessment for the duration of one year~* Age \>= 25 years~* Polypoidal Choroidal Vasculopathy as noted on fluorescein and ICG angiography: active leakage, active bleeding or recent decrease in vision~* BCVA using ETDRS 20/32 to 20/400~Exclusion Criteria:~* Any history of previous vitrectomy~* Previous cataract or ocular surgery within 2 months of day 0~* Active intraocular inflammation in the study eye~* Active infections conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye~* Participation with another investigational drug within the past 30 days~* Prior sodium pegaptanib, verteporfin photodynamic therapy, intravitreal steroids, or bevacizumab within 30 days of study entry~* Blood pressure \>180/110 (use of antihypertensives is allowed as long as hypertension can be controlled and is stable)~* Pregnancy

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Single Arm study (Type: OTHER): Single arm study:~Drug: ranibizumab intravitreal injection liquid, 0.5 mg ranibizumab intravitreally, once a month for 1 year

Based on this trial design, predict the completion outcome and termination type (if applicable).